Squarepoint
RANI icon

Squarepoint’s Rani Therapeutics RANI Stock Holding History

Squarepoint’s Portfolio RANI Stock Details RANI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$12.1K Sell
16,401
-327,977
-95% -$419K ﹤0.01% 4184
2025
Q4 		$465K Buy
+344,378
New +$520K ﹤0.01% 3271
2025
Q1 		– Sell
-10,863
Closed -$14.9K – 5252
2024
Q4 		$14.9K Buy
+10,863
New +$22.8K ﹤0.01% 4949
2022
Q1 		– Sell
-50,000
Closed -$818K – 3390
2021
Q4 		$818K Hold
50,000
– – ﹤0.01% 1824
2021
Q3 		$891K Buy
+50,000
New +$865K ﹤0.01% 1627

Other funds holding RANI

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCP
SymBiosis Capital Partners Bentonville, Arkansas $52.8M AUM
LP
Longaeva Partners Chicago, Illinois $2.7B AUM 37.16% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NFGH
Nan Fung Group Holdings Kai Tak, Hong Kong $121M AUM 56.89% 1-Year Est. Return

Squarepoint's RANI Position: Q1 2026 in Review

Squarepoint reduced its Rani Therapeutics (RANI) stake by 95% in Q1 2026, selling an estimated $419K and leaving 16,401 shares worth $12.1K. The position accounts for ﹤0.01% of the portfolio, ranked #4184.

Squarepoint first reported a position in RANI in Q3 2021 and has held it in 5 quarters since. The position peaked at $891K in Q3 2021. 74 funds tracked by Wall St. Rank hold RANI as of Q1 2026.

  • Squarepoint held 16,401 shares of Rani Therapeutics worth $12.1K as of Q1 2026.
  • Squarepoint sold 327,977 Rani Therapeutics shares in Q1 2026, an estimated $419K.
  • Rani Therapeutics made up ﹤0.01% of Squarepoint's portfolio in Q1 2026, its #4184 holding.
  • Squarepoint first reported a position in Rani Therapeutics in Q3 2021 and has held it in 5 quarters since.
  • Squarepoint's Rani Therapeutics position peaked at $891K in Q3 2021.
  • 74 funds tracked by Wall St. Rank held Rani Therapeutics as of Q1 2026.

Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.